NCT05272384 2026-03-18
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
1 trialsLymphoma, Large B-Cell, Diffuse × decitabine and cedazuridine drug combination × 90 days × Clear all